Hudson Bay Capital Management
VIR icon

Hudson Bay Capital Management’s Vir Biotechnology VIR Stock Holding History

Hudson Bay Capital Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.9M Sell
1,364,000
-105,510
-7% -$1M 0.04% 291
2026
Q1 		$13.2M Buy
1,469,510
+144,510
+11% +$1.15M 0.05% 263
2025
Q4 		$7.99M Buy
1,325,000
+413,118
+45% +$2.46M 0.03% 384
2025
Q3 		$5.21M Buy
911,882
+215,882
+31% +$1.1M 0.02% 532
2025
Q2 		$3.51M Buy
696,000
+104,580
+18% +$561K 0.01% 647
2025
Q1 		$3.83M Sell
591,420
-258,453
-30% -$2.3M 0.01% 671
2024
Q4 		$6.24M Buy
849,873
+321,631
+61% +$2.54M 0.02% 458
2024
Q3 		$3.96M Buy
528,242
+103,242
+24% +$897K 0.02% 464
2024
Q2 		$3.78M Buy
425,000
+140,000
+49% +$1.34M 0.02% 425
2024
Q1 		$2.89M Sell
285,000
-5,000
-2% -$50.9K 0.02% 407
2023
Q4 		$2.92M Buy
290,000
+82,500
+40% +$754K 0.02% 393
2023
Q3 		$1.94M Buy
207,500
+197,500
+1,975% +$2.82M 0.02% 488
2023
Q2 		$245K Buy
+10,000
New +$251K ﹤0.01% 655

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Hudson Bay Capital Management's VIR Position: Q2 2026 in Review

Hudson Bay Capital Management reduced its Vir Biotechnology (VIR) stake by 7.2% in Q2 2026, selling an estimated $1M and leaving 1,364,000 shares worth $13.9M. The position accounts for 0.04% of the portfolio, ranked #291.

Hudson Bay Capital Management first reported a position in VIR in Q2 2023 and has held it in 13 quarters since. 237 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Hudson Bay Capital Management held 1,364,000 shares of Vir Biotechnology worth $13.9M as of Q2 2026.
  • Hudson Bay Capital Management sold 105,510 Vir Biotechnology shares in Q2 2026, an estimated $1M.
  • Vir Biotechnology made up 0.04% of Hudson Bay Capital Management's portfolio in Q2 2026, its #291 holding.
  • Hudson Bay Capital Management first reported a position in Vir Biotechnology in Q2 2023 and has held it in 13 quarters since.
  • 237 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Hudson Bay Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.